CompletedPhase 3

Long-term Study of SYR-472

Japan680 participantsStarted 2011-09-01

Plain-language summary

To evaluate the safety and efficacy of long-term treatment with SYR-472 in diabetic patients.

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The participant is an outpatient.
✓. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
✓. Diabetes Mellitus

✕. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
✕. The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.

Adverse events

Timeframe: 52 weeks.

NCT IDNCT01431807

SponsorTakeda

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-06-01